@article{oai:nagasaki-u.repo.nii.ac.jp:00020231,
 author = {Maeda, Kanenori and Noguchi, Mitsuru and Nomata, Koichiro and Koga, Shigehiko and Kanetake, Hiroshi},
 issue = {1-2},
 journal = {Acta medica Nagasakiensia},
 month = {Jun},
 note = {Background: Pyrimidine nucleoside phosphorylase (PyNPase) is an enzyme that converts 5'-deoxy-5-fluorouridine to 5- fluorouracil. PyNPase is identical to platelet-derived endothelial cell growth factor (PD-ECGF), and has angiogenic activity. In the present study of PyNPase activity in renal cell carcinoma, we tested for correlation between PyNPase activity and tumor extension, tumor proliferation and clinical characteristics. Methods: Samples of tumor tissue and non-tumor tissue were obtained from 10 renal cell carcinoma patients who underwent radical nephrectomy. These samples were examined, and PyNPase activity of the tissues was assayed. Results: PyNPase activity was significantly higher in renal cancer tissue than in normal tissue (p<0.01), and in immunohistochemical assays PyNPase was strongly stained in the cytoplasm of renal cancer cells. However, there were no significant correlation between PyNPase activity and tumor extension, according to the results of histopathological examination and evaluation of vascularity of renal cancer tumor tissue. Conclusion: In this study, we did not observe correlation between PyNPase activity and renal cancer extension and proliferation. However, the present data suggest that pyrimidine-class drugs may be useful against renal cell carcinoma, because PyNPase activity is significantly higher in renal cancer tissue than in normal tissue., Acta medica Nagasakiensia. 2001, 46(1-2), p.27-31},
 pages = {27--31},
 title = {Elevated Expression of Pyrimidine Nucleoside Phosphorylase (PyNPase) in Renal Cell Carcinoma Tissue},
 volume = {46},
 year = {2001}
}